
Marsh & McLennan faces cyclical headwinds and margin pressure, prompting a downgrade to 'Hold' despite solid execution and strategic initiatives. Q3 2026 saw MRSH beat revenue and EPS estimates, but underlying growth slowed as P&C pricing trends and reinsurance weakness weighed on results. Cost-cutting targets were raised to $600 million by 2028, but inflation and wage pressures continue to erode operating margins, now at 17.7%.










